Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kala Pharmaceuticals Inc (KALA)

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,712
  • Shares Outstanding, K 73,208
  • Annual Sales, $ 11,240 K
  • Annual Income, $ -142,610 K
  • 60-Month Beta 1.04
  • Price/Sales 2.15
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KALA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.94
  • Most Recent Earnings -0.38 on 08/11/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 64.42%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,311.19% on 06/16/22
  • IV Low 0.00% on 08/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,785
  • Open Int (30-Day) 3,674

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +41.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2900 +6.90%
on 08/11/22
0.4300 -27.91%
on 08/11/22
-0.0368 (-10.61%)
since 07/19/22
3-Month
0.2810 +10.32%
on 07/01/22
0.8499 -63.53%
on 05/23/22
-0.3715 (-54.51%)
since 05/19/22
52-Week
0.2810 +10.32%
on 07/01/22
3.6100 -91.41%
on 09/01/21
-2.4500 (-88.77%)
since 08/19/21

Most Recent Stories

More News
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates

Kala Pharma (KALA) delivered earnings and revenue surprises of 13.64% and 18.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

KALA : 0.3100 (-4.29%)
USAQ : 0.1975 (-3.66%)
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received...

KALA : 0.3100 (-4.29%)
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 11.11% and 12.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

AQB : 1.3200 (-2.22%)
KALA : 0.3100 (-4.29%)
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the...

KALA : 0.3100 (-4.29%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory...

KALA : 0.3100 (-4.29%)
Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the...

KALA : 0.3100 (-4.29%)
Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade

Kala Pharma (KALA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KALA : 0.3100 (-4.29%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., June 17, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory...

KALA : 0.3100 (-4.29%)
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the...

KALA : 0.3100 (-4.29%)
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments----Kala Will Focus Resources on Phase 2/3...

KALA : 0.3100 (-4.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes,...

See More

Key Turning Points

3rd Resistance Point 0.3379
2nd Resistance Point 0.3289
1st Resistance Point 0.3194
Last Price 0.3100
1st Support Level 0.3009
2nd Support Level 0.2919
3rd Support Level 0.2824

See More

52-Week High 3.6100
Fibonacci 61.8% 2.3383
Fibonacci 50% 1.9455
Fibonacci 38.2% 1.5527
Last Price 0.3100
52-Week Low 0.2810

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar